Literature DB >> 20978278

Creation of a knowledge management system for QT analyses.

Christoffer W Tornøe1, Christine E Garnett, Yaning Wang, Jeffry Florian, Michael Li, Jogarao V Gobburu.   

Abstract

An increasing number of thorough QT (TQT) reports are being submitted to the US Food and Drug Administration's interdisciplinary review team for QT (IRT-QT), requiring time-intensive quantitative analyses by a multidisciplinary review team within 45 days. This calls for systematic learning to guide future trials and policies by standardizing and automating the QT analyses to improve review efficiency, provide consistent advice, and enable pooled data analyses to answer key regulatory questions. The QT interval represents the time from initiation of ventricular depolarization to completion of ventricular repolarization recorded by electrocardiograph (ECG) and is used in the proarrhythmic risk assessment. The developed QT knowledge management system is implemented in the R package "QT." Data from 11 crossover TQT studies including time-matched ECGs and pharmacokinetic measurements following single doses of 400 to 1200 mg moxifloxacin were used for the QT analysis example. The automated workflow was divided into 3 components (data management, analysis, and archival). The generated data sets, scripts, tables, and graphs are automatically stored in a queryable repository and summarized in an analysis report. More than 100 TQT studies have been analyzed using the system since 2007. This has dramatically reduced the time needed to review TQT studies and has made the IRT-QT reviews consistent across reviewers. Furthermore, the system enables leveraging prior knowledge through pooled data analyses to answer policy-related questions and to understand the various effects that influence study results.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20978278     DOI: 10.1177/0091270010378408

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  31 in total

1.  Implications of the IQ-CSRC Prospective Study: Time to Revise ICH E14.

Authors:  Borje Darpo; Christine Garnett; James Keirns; Norman Stockbridge
Journal:  Drug Saf       Date:  2015-09       Impact factor: 5.606

2.  Correcting QT for Heart Rate When Both are Affected by a Drug.

Authors:  Georg Ferber
Journal:  Drug Saf       Date:  2019-03       Impact factor: 5.606

Review 3.  Early QT assessment--how can our confidence in the data be improved?

Authors:  Borje Darpo; Christine Garnett
Journal:  Br J Clin Pharmacol       Date:  2013-11       Impact factor: 4.335

Review 4.  Dealing with global safety issues : was the response to QT-liability of non-cardiac drugs well coordinated?

Authors:  Norman Stockbridge; Joel Morganroth; Rashmi R Shah; Christine Garnett
Journal:  Drug Saf       Date:  2013-03       Impact factor: 5.606

5.  Lomitapide at supratherapeutic plasma levels does not prolong the Qtc interval--results from a TQT study with moxifloxacin and ketoconazole.

Authors:  Borje Darpo; Georg Ferber; Meijian Zhou; Mark Sumeray; Philip Sager
Journal:  Ann Noninvasive Electrocardiol       Date:  2013-09-30       Impact factor: 1.468

6.  Effects of atomoxetine on the QT interval in healthy CYP2D6 poor metabolizers.

Authors:  Corina Loghin; Harry Haber; Charles M Beasley; Prajakti A Kothare; Lynnette Kauffman; John April; Ling Jin; Albert J Allen; Malcolm I Mitchell
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

Review 7.  Scientific white paper on concentration-QTc modeling.

Authors:  Christine Garnett; Peter L Bonate; Qianyu Dang; Georg Ferber; Dalong Huang; Jiang Liu; Devan Mehrotra; Steve Riley; Philip Sager; Christoffer Tornoe; Yaning Wang
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-12-05       Impact factor: 2.745

8.  A phase I, open-label, single-arm study for QT assessment of eribulin mesylate in patients with advanced solid tumors.

Authors:  Thierry Lesimple; Julien Edeline; Timothy J Carrothers; Frédérique Cvitkovic; Borje Darpo; Jean-Pierre Delord; Hervé Léna; Nicolas Penel; Geoff J Edwards; Kenneth Law; Jantien Wanders; Allan Kristensen; Larisa Reyderman
Journal:  Invest New Drugs       Date:  2012-11-11       Impact factor: 3.850

9.  Modelling of drug-induced QT-interval prolongation: estimation approaches and translational opportunities.

Authors:  Eleonora Marostica; Karel Van Ammel; Ard Teisman; Koen Boussery; Jan Van Bocxlaer; Filip De Ridder; David Gallacher; An Vermeulen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-08-11       Impact factor: 2.745

10.  Albiglutide Does Not Prolong QTc Interval in Healthy Subjects: A Thorough ECG Study.

Authors:  Borje Darpo; Meijian Zhou; Jessica Matthews; Hui Zhi; Malcolm A Young; Caroline Perry; Rickey R Reinhardt
Journal:  Diabetes Ther       Date:  2014-02-08       Impact factor: 2.945

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.